The Conference Board Consumer Confidence Index fell 3.8 points in December, extending a late-year slide that economists say signals growing caution among U.S. households. After ... Read moreThe post C ...

Abstract: Detecting small objects in remote sensing images is challenging due to complex background interference, the tendency for them to be misse, and multi-scale variations. These challenges lead ...

Icotrokinra, a small peptide, is challenging the dominance of traditional biologics in psoriasis Medicaid coverage for Janus kinase inhibitors in alopecia is limited, with significant access barriers ...

Among patients with ischemic cardiomyopathy and ventricular tachycardia (VT), catheter ablation as a first-line strategy over antiarrhythmic drugs (AAD) was associated with a lower risk of the primary ...

AAD HEALTHCARE PRIVATE LIMITED is a Private Limited Company, governed by the Companies Act as a company limited by shares. Classified as a Non-government company, it is registered under the Registrar ...

The current guidelines on the use of biologic agents for the treatment of psoriasis were jointly released in 2019 Joint American Academy of Dermatology (AAD) and National Psoriasis Foundation (NPF) ...

Please provide your email address to receive an email when new articles are posted on . This is the third update to the guidelines for treating and managing atopic dermatitis in the last 2 years. The ...

A panelist discusses how real-world evidence from a large cohort study (n = 31521) presented at AAD 2025 reveals notable differences in treatment patterns, discontinuation rates, persistence, and ...

Advance press registration deadline: Wednesday, Feb. 25, 2026, at 12 p.m. CT. After this date, you must submit your application on-site. Housing deadline: Wednesday, March 4, at 12 p.m. CT. The ...

Christopher J. Sayed, MD, reports on how the 2025 American Academy of Dermatology Annual Meeting was an exciting event for hidradenitis suppurativa (HS), with increasing buzz and interest in the ...

New data analysis on Tirbanibulin shows consistent treatment response for actinic keratosis (AK): data from phase IV and real-world evidence studies show consistently high levels of response as well ...